Who are GSK2340272A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GSK2340273A, GSK5764227, ASP7374, Placebo to match deucravacitinib, GSK2340274A, GSK3511294.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gsk2340272a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

GSK2340272A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GSK2340272A (GSK2340272A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TYK2 inhibitor. Area: Immunology.

phase 3 TYK2 inhibitor TYK2 (tyrosine kinase 2) Immunology Biologic Live · refreshed every 30 min

Target snapshot

GSK2340272A (GSK2340272A) — GlaxoSmithKline. GSK2340272A is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GSK2340272A TARGET	GSK2340272A	GlaxoSmithKline	phase 3	TYK2 inhibitor	TYK2 (tyrosine kinase 2)
GSK2340273A	GSK2340273A	GlaxoSmithKline	phase 3	TYK2 inhibitor	TYK2 (tyrosine kinase 2)
GSK5764227	GSK5764227	GlaxoSmithKline	phase 3	TYK2 inhibitor	TYK2 (tyrosine kinase 2)
ASP7374	ASP7374	UMN Pharma Inc.	phase 3	TYK2 inhibitor	TYK2 (tyrosine kinase 2)
Placebo to match deucravacitinib	Placebo to match deucravacitinib	Takeda	phase 3	TYK2 inhibitor	TYK2
GSK2340274A	GSK2340274A	GlaxoSmithKline	phase 3	TYK2 inhibitor	TYK2 (tyrosine kinase 2)
GSK3511294	GSK3511294	GlaxoSmithKline	phase 3	TYK2 inhibitor	TYK2 (tyrosine kinase 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TYK2 inhibitor class)

GlaxoSmithKline · 6 drugs in this class
Takeda · 1 drug in this class
UMN Pharma Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK2340272A — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk2340272a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing